Skip to main content
. 2022 Jul 28;8:51. doi: 10.1186/s40942-022-00401-4

Table 4.

The distribution of patients according to the additional injections required during the week 12 to week 48

Treatment Between 12 and 16 weeks Between 20 and 24 weeks Between 28 and 32 weeks Between 36 and 40 weeks Between 44 and 48 weeks
Brolucizumab (n = 56) 3 (5.4%) 17 (30.4%) 3 (5.4%) 1 (1.8%) 2 (3.6%)
Aflibercept (n = 58) 23 (39.7%) 21 (36.2%) 13 (22.4%) 12 (20.7%) 8 (13.8%)